ATLANTA, GA — A multicenter controlled trial testing the ability of an aldose reductase inhibitor to stabilize early-stage asymptomatic diabetic cardiomyopathy missed its primary endpoint, researchers ...

Please provide your email address to receive an email when new articles are posted on . Adults with diabetes with cardiomyopathy were at significantly higher risk for developing incident HF, according ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM), an independent diabetes complication, is characterized by abnormalities in ...

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders. This often ...

Illustration of the role of exosomes in diabetic cardiomyopathy (DCM). In response to diabetes, normal cardiomyocytes undergo pathological changes, leading to the release of detrimental exosomes.

Compared with placebo, a significant improvement in cardiac functional capacity was observed among caficrestat-treated patients not receiving concomitant SGLT2is or GLP-1 RAs. Treatment with ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM), an independent diabetes complication, is characterized by abnormalities in ...

Authors say these identified patients may benefit from more aggressive heart failure preventive strategies. (HealthDay News) — Machine learning can help identify individuals with diabetes at high risk ...

AT-001 (also called caficrestat) is an investigational oral, novel, potent Aldose Reductase inhibitor in Phase 3 clinical development for the treatment of Diabetic Cardiomyopathy. The global ARISE-HF ...

Diabetes, obesity and heart disease are on the rise. More Americans are overweight. Increasing obesity in the U.S. correlates with increasing diabetes rates, which then correlates with increasing ...